Cases & Deals

  • Home
  • Practices
  • Suzhou Abogen Biosciences establishes global patent portfolios for mRNA-based vaccines and nano-delivery platform technologies

Share

Suzhou Abogen Biosciences establishes global patent portfolios for mRNA-based vaccines and nano-delivery platform technologies

November 2022

Client(s) Suzhou Abogen Biosciences Co., Ltd.

Jones Day represents Suzhou Abogen Biosciences Co., Ltd. in the establishment and prosecution of global patent portfolios related to mRNA-based vaccines for infectious diseases, such as COVID-19, as well as nano-delivery platform technologies.

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.